Format

Send to

Choose Destination
Curr Top Med Chem. 2005;5(2):215-29.

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.

Author information

1
Array BioPharma Inc., 3200 Walnut Street, Boulder, CO 80301, USA. Eli.Wallace@arraybiopharma.com

Abstract

This paper reviews recent progress in the design and evaluation of MEK inhibitors as cancer therapeutics. Activation of the Ras / Raf / MEK / MAP kinase pathway has been implicated in uncontrolled cell proliferation and tumor growth. Mutated, oncogenic forms of Ras are found in 50% of colon, 90% of pancreatic and 30% of lung cancers. Recently, B-Raf mutations have been identified in more than 60% of malignant melanomas and from 40-70% of papillary thyroid cancers. MEK, a dual specificity kinase, is a key player in this pathway; it is downstream of both Ras and Raf and activates ERK1/2 through phosphorylation of key tyrosine and threonine residues. Representative examples of both ATP competitive and non-competitive inhibitors as well as natural product based inhibitors will be discussed.

PMID:
15853648
DOI:
10.2174/1568026053507723
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center